Psychiatric and non-psychiatric drugs causing false-positive amphetamines urine test in psychiatric patients: a pharmacovigilance analysis using FAERS.
Vera BattiniGiovanna CirnigliaroLuca GiacovelliMaria BoscacciSilvia Massara ManzoGiulia MosiniGreta GuarnieriMichele GringeriBeatrice BenattiEmilio ClementiBernardo M Dell'OssoCarla CarnovalePublished in: Expert review of clinical pharmacology (2023)
False-positive results were described in literature for antidepressants, atomoxetine, methylphenidate, and antipsychotics, but also for non-psychiatric drugs of common use, such as labetalol, fenofibrate, and metformin. Immunoassay method is usually responsible for false-positive results, and in most cases, mass spectrometry (MS) does not eventually confirm the UDS positivity. Physicians should be aware of immunoassays' limitations and when turning to a confirmatory test. Any new cross-reaction should be reported to pharmacovigilance activities.
Keyphrases
- mental health
- mass spectrometry
- attention deficit hyperactivity disorder
- end stage renal disease
- drug induced
- ejection fraction
- systematic review
- newly diagnosed
- adverse drug
- liquid chromatography
- chronic kidney disease
- prognostic factors
- multiple sclerosis
- emergency department
- ms ms
- autism spectrum disorder
- high resolution
- sensitive detection
- patient reported outcomes